Literature DB >> 9105219

Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers.

A F Kopman1, P S Yee, G G Neuman.   

Abstract

BACKGROUND: Recovery of the train-of-four (TOF) ratio to a value > 0.70 is synonymous with adequate return of neuromuscular function, but there is little information available concerning the subjective experience that accompanies residual neuromuscular block wherein the TOF ratio is in the range of 0.70 to 0.90.
METHODS: Ten American Society of Anesthesiologists' (ASA) physical status 1 volunteers were studied. Control measurements including grip strength in kilograms and ability to perform a 5-s head- and leg-lift. In addition, a standard wooden tongue depressor was placed between each subject's incisor teeth, and he or she was told not to let the investigator remove it. All subjects were easily able to retain the device despite vigorous attempts to dislodge it. Neuromuscular function was monitored with a Datex (Datex Medical Instrumentation, Inc., Tewksbury, MA) 221 electromyographic (EMG) monitor. TOF stimulation was given every 20 s, and the measured TOF fade ratio was continuously recorded. A 5 mg/kg bolus of mivacurium was then administered, and an infusion at 2 mg.kg-1.min-1 was begun. The infusion was continued until the TOF ratio decreased to < 0.70 and was adjusted to keep it in the range of 0.65 to 0.75. Signs and symptoms of weakness were recorded when the TOF ratio had been stable +/-0.03 for at least 10 min during an interval when there were no adjustments in the infusion. All tests noted previously were repeated at this time. The TOF ratio was then allowed to recover to 0.85-0.90. When stable at this level, all tests were repeated, and the infusion was discontinued. TOF measurements were continued until a ratio of 1.0 was attained and until a final set of observations was recorded.
RESULTS: The TOF ratio in all subjects was reduced to < 0.70. No volunteers required intervention to maintain a patient airway, and the hemoglobin oxygen saturation while breathing air was > or = 96% at all times. TOF ratios < or = 0.90 were accompanied by diplopia and difficulty in tracking moving objects in all subjects. The ability to strongly oppose the incisor teeth did not return until the TOF ratio (on average) exceeded 0.85. A sustained 5-s head-lift was not achieved until the TOF ratio averaged 0.60 (range, 0.45-0.75). At a TOF ratio of 0.70, grip strength averaged 59% of control (range, 50-75%). With certain exceptions (vision, ability to clench the teeth tightly), there was wide variation in symptomatology between patients for any given TOF ratio. It is impossible to give reliable TOF break-points at which symptoms and signs will be present or absent.
CONCLUSIONS: All subjects had significant signs and symptoms of residual block at a TOF ratio of 0.70; none considered themselves remotely "street ready" at this time. The authors believe that satisfactory recovery of neuromuscular function after mivacurium-induced neuromuscular block requires return of the TOF ratio to a value > 0.90 and ideally to unity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105219     DOI: 10.1097/00000542-199704000-00005

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  27 in total

1.  Retrospective analysis of spontaneous recovery from neuromuscular blockade produced by empirical use of rocuronium.

Authors:  Hiroto Yamamoto; Tokujiro Uchida; Yudai Yamamoto; Yusuke Ito; Koshi Makita
Journal:  J Anesth       Date:  2011-09-21       Impact factor: 2.078

2.  A pharmacokinetic-pharmacodynamic model for neuromuscular blocking agents to predict train-of-four twitches.

Authors:  Douglas J Eleveld; Ann De Haes; Johannes H Proost; J Mark Wierda
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

3.  Delayed Recovery from Anaesthesia: Missing Information.

Authors:  Karthikeyan Kallidaikurichi Srinivasan
Journal:  J Clin Diagn Res       Date:  2016-10-01

4.  Neostigmine Versus Sugammadex for Reversal of Neuromuscular Blockade and Effects on Reintubation for Respiratory Failure or Newly Initiated Noninvasive Ventilation: An Interrupted Time Series Design.

Authors:  Martin Krause; Shannon K McWilliams; Kenneth J Bullard; Lena M Mayes; Leslie C Jameson; Susan K Mikulich-Gilbertson; Ana Fernandez-Bustamante; Karsten Bartels
Journal:  Anesth Analg       Date:  2020-07       Impact factor: 5.108

Review 5.  Neuromuscular monitoring: an update.

Authors:  Mădălina Duţu; Robert Ivaşcu; Oana Tudorache; Darius Morlova; Alina Stanca; Silvius Negoiţă; Dan Corneci
Journal:  Rom J Anaesth Intensive Care       Date:  2018-04

6.  [EzPAP® therapy of postoperative hypoxemia in the recovery room : experiences with the new compact system of end-expiratory positive airway pressure].

Authors:  A D Rieg; C Stoppe; R Rossaint; M Coburn; M Hein; G Schälte
Journal:  Anaesthesist       Date:  2012-09-27       Impact factor: 1.041

Review 7.  [Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].

Authors:  C Unterbuchner; K Ehehalt; B Graf
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

8.  International survey of neuromuscular monitoring in two European countries: a questionnaire study among Hungarian and Romanian anaesthesiologists.

Authors:  Adrienn Pongrácz; Réka Nemes; Caius Breazu; László Asztalos; Ileana Mitre; Edömér Tassonyi; Béla Fülesdi; Calin Mitre
Journal:  Rom J Anaesth Intensive Care       Date:  2019-04

9.  A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.

Authors:  Yiling Jiang; Lori D Bash; Leif Saager
Journal:  Adv Ther       Date:  2021-04-19       Impact factor: 3.845

10.  Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant.

Authors:  Vladimir Nigrovic; Shashi B Bhatt; Anton Amann
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-21       Impact factor: 2.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.